Reneo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPHM research report →
Price Chart
About the company
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist.
- CEO
- Gregory J. Flesher
- IPO
- 2021
- Employees
- 8
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on RPHM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.84M
- P/E
- -5.21
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 5.27
- EV/EBITDA
- 3.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -12.81%
- ROIC
- -35.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-62,950,000
- Net Income
- $0+0.0%
- EPS
- $-4.40+0.0%
- OCF Growth
- -1.4%
- FCF Growth
- -1.4%
- 52W High
- $82.90
- 52W Low
- $1.68
- 50D MA
- $14.92
- 200D MA
- $16.09
- Beta
- 0.22
- RSI (14)
- 70
- Avg Volume
- 17.98K
No earnings-call transcripts are available for RPHM yet.
- Free Float
- 99.5%
- Shares Outstanding
- 3.34M
- Float Shares
- 3.33M
of shares held by institutions
50 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rivervest Venture Management LLC | 2.53M | 0 |
| Blackrock Inc. | 293.65K | ▼ 700.01K |
| Point72 Middle East Fze | 13.95K | ▲ 13.95K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 24 | Leonard Braden Michael | buy | 68,746 |
| Sep 24, 24 | Leonard Braden Michael | buy | 29,600 |
| Sep 18, 24 | Leonard Braden Michael | buy | 806 |
| Sep 17, 24 | Leonard Braden Michael | buy | 55,300 |
| Sep 16, 24 | Leonard Braden Michael | buy | 172,747 |
| Sep 13, 24 | Leonard Braden Michael | buy | 150,000 |
| Sep 12, 24 | Leonard Braden Michael | buy | 36,176 |
| Aug 14, 24 | Leonard Braden Michael | buy | 100,487 |
| Aug 13, 24 | Leonard Braden Michael | buy | 171,339 |
| May 14, 24 | Leonard Braden Michael | buy | 335,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RPHM coverage
Recent articles, reports, and earnings notes.
No research on RPHM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RPHM report →OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
globenewswire.com · Oct 4
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
globenewswire.com · Oct 2
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
businesswire.com · Sep 3
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
globenewswire.com · Aug 13
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
globenewswire.com · Jun 26
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
prnewswire.com · Jun 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
globenewswire.com · Jun 21
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
globenewswire.com · Jun 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.